Raiffeisen Bank International AG Has $73.54 Million Stock Position in Thermo Fisher Scientific Inc. $TMO

Raiffeisen Bank International AG raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 48.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 159,161 shares of the medical research company’s stock after buying an additional 52,118 shares during the quarter. Thermo Fisher Scientific accounts for 1.0% of Raiffeisen Bank International AG’s portfolio, making the stock its 19th largest position. Raiffeisen Bank International AG’s holdings in Thermo Fisher Scientific were worth $73,539,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in Thermo Fisher Scientific by 0.7% during the 3rd quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 5,107 shares of the medical research company’s stock worth $2,477,000 after purchasing an additional 36 shares in the last quarter. Bridgewater Advisors Inc. raised its position in Thermo Fisher Scientific by 1.6% during the third quarter. Bridgewater Advisors Inc. now owns 2,388 shares of the medical research company’s stock valued at $1,158,000 after buying an additional 38 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Thermo Fisher Scientific in the 3rd quarter worth about $1,924,000. Mendel Money Management grew its stake in Thermo Fisher Scientific by 1.0% during the 3rd quarter. Mendel Money Management now owns 11,413 shares of the medical research company’s stock valued at $5,536,000 after acquiring an additional 109 shares in the last quarter. Finally, Northern Financial Advisors Inc acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $234,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on TMO shares. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st. Robert W. Baird set a $653.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. HSBC raised Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. Morgan Stanley upped their target price on Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 2nd. Finally, KeyCorp raised Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target for the company in a research note on Sunday, December 7th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $633.68.

Insider Activity

In related news, EVP Michael D. Shafer sold 10,725 shares of the business’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the completion of the transaction, the executive vice president owned 18,731 shares of the company’s stock, valued at approximately $11,238,600. The trade was a 36.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michel Lagarde sold 32,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $583.39, for a total value of $18,668,480.00. Following the completion of the sale, the chief operating officer directly owned 65,480 shares in the company, valued at $38,200,377.20. This trade represents a 32.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 108,996 shares of company stock worth $63,355,935. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $510.96 on Friday. The business’s 50-day simple moving average is $579.25 and its 200-day simple moving average is $545.43. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The firm has a market cap of $191.97 billion, a price-to-earnings ratio of 28.80, a P/E/G ratio of 2.97 and a beta of 0.93.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The firm had revenue of $12.22 billion during the quarter, compared to analysts’ expectations of $11.95 billion. During the same quarter in the prior year, the business earned $6.10 earnings per share. The company’s revenue was up 7.2% on a year-over-year basis. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its board has approved a stock buyback plan on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board of directors believes its shares are undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.